In the fourth quarter, Instil reported a net loss of $8.2 million, translating to a loss per share of $1.21, compared to a net loss of $11.9 million and a loss per share of $1.82 for the same period in 2024. For the full year, the net loss was $71.4 million, or $10.70 per share, compared to a net loss of $74.1 million, or $11.39 per share, in 2024. The company’s operational expenses included $3.5 million in research and development for Q4 2025, up from $1.1 million in Q4 2024, indicating a ramp-up in its clinical development efforts.
Instil Bio's CEO, Bronson Crouch, emphasized the company's commitment to identifying high-quality opportunities that can enhance long-term shareholder value. The company is focused on leveraging its balance sheet to pursue strategic acquisitions that could provide access to promising therapeutic candidates across various areas.
Despite the challenges faced in 2025, including the discontinuation of clinical development for AXN-2510, Instil is optimistic about its future prospects. The company aims to sharpen its strategic focus and position itself for growth through disciplined capital deployment and external innovation.
Investors are encouraged to monitor Instil Bio's progress as it navigates this pivotal phase in its development, with the potential for significant advancements in its therapeutic pipeline.
